Phase 1 study of temozolomide associated with topotecan in refractory or relapsed malignant tumors in children and adolescents
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Temozolomide (Primary) ; Topotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 11 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Aug 2009 Biomarkers information updated
- 18 Sep 2007 Status changed from initiated to recruiting.